Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?

Nagasaka, 2021, Lorlatinib should be considered as the preferred first-line option in patients with advanced ALK-rearranged NSCLC, J. Thorac. Oncol., 16, 532, 10.1016/j.jtho.2020.12.021 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N. Engl. J. Med., 371, 2167, 10.1056/NEJMoa1408440 Solomon, 2018, Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer, J. Clin. Oncol., 36, 2251, 10.1200/JCO.2017.77.4794 Wu, 2018, Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer, J. Thorac. Oncol., 13, 1539, 10.1016/j.jtho.2018.06.012 Soria, 2017, First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomized, open-label, phase 3 study, Lancet, 389, 917, 10.1016/S0140-6736(17)30123-X Peters, 2017, Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer, N. Engl. J. Med., 377, 829, 10.1056/NEJMoa1704795 Camidge, 2019, Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study, J. Thorac. Oncol., 14, 1233, 10.1016/j.jtho.2019.03.007 Hida, 2017, Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomized phase 3 trial, Lancet, 390, 29, 10.1016/S0140-6736(17)30565-2 Nakagawa, 2020, Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer, Lung Cancer, 139, 195, 10.1016/j.lungcan.2019.11.025 Zhou, 2019, Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomized phase 3 study, Lancet Respir. Med., 7, 437, 10.1016/S2213-2600(19)30053-0 Camidge, 2018, Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer, N. Engl. J. Med., 379, 2027, 10.1056/NEJMoa1810171 Camidge, 2020, Brigatinib versus crizotinib in advanced ALK inhibitor-I ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L Trial, J. Clin. Oncol., 38, 3592, 10.1200/JCO.20.00505 Selvaggi, 2020, Phase 3 Randomized study of ensartinib vs crizotinib in anaplastic lymphoma kinase (ALK)–positive NSCLC patients: eXalt3, J. Thorac. Oncol., 15, 10.1016/j.jtho.2020.08.003 Shaw, 2020, First-Line Lorlatinib or crizotinib in advanced ALK-positive lung cancer, N. Engl. J. Med., 383, 2018, 10.1056/NEJMoa2027187 Drilon, 2018, Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers, J. Thorac. Oncol., 13, 1595, 10.1016/j.jtho.2018.07.004 Gadgeel, 2018, Alectinib versus crizotinib in treatInaive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study, Ann. Oncol., 29, 2214, 10.1093/annonc/mdy405 Nishio, 2018, Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer, Lung Cancer, 121, 37, 10.1016/j.lungcan.2018.04.015 Horn, 2019, Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer, J. Thorac. Oncol., 14, 1901, 10.1016/j.jtho.2019.08.003 Gainor, 2016, Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer, Cancer Discov., 6, 1118, 10.1158/2159-8290.CD-16-0596 Qiao, 2016, Cracking the code of resistance across Multiple Lines of ALK inhibitor therapy in lung cancer, Cancer Discov., 6, 1084, 10.1158/2159-8290.CD-16-0910 Johnson, 2014, J. Med. Chem., 57, 4720, 10.1021/jm500261q Zou, 2015, PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models, Cancer Cell, 28, 70, 10.1016/j.ccell.2015.05.010 Camidge, 2021, Lorlatinib should not be considered as the preferred first-line option in patients with advanced ALK rearranged NSCLC, J. Thorac. Oncol., 16, 528, 10.1016/j.jtho.2020.12.022 Yoda, 2018, Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer, Cancer Discov., 8, 714, 10.1158/2159-8290.CD-17-1256 Dagogo-Jack, 2019, Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity, Clin. Cancer Res., 25, 6662, 10.1158/1078-0432.CCR-19-1436 Okada, 2019, Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance, EBioMedicine, 10.1016/j.ebiom.2019.01.019 Zhu, 2020, A novel sequentially evolved EML4-ALK v3 G1202R/S1206Y in cis double mutation confers resistance to lorlatinib: a brief report and literature review, JTO Clin. Res. Rep., 2 Papadopoulos, 2020, U.S. phase I first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors, Clin. Cancer Res., 26, 4785, 10.1158/1078-0432.CCR-20-1630 Lin, 2021, Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer, Clin. Cancer Res., 27, 2899, 10.1158/1078-0432.CCR-21-0032 Solomon, 2018, Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study, Lancet Oncol., 19, 1654, 10.1016/S1470-2045(18)30649-1 Zhu, 2020, An International real-world analysis of the efficacy and safety of lorlatinib through early or expanded access programs in patients with tyrosine kinase inhibitor-refractory ALK-positive or ROS1-positive NSCLC, J. Thorac. Oncol., 15, 1484, 10.1016/j.jtho.2020.04.019 Lin, 2018, Brigatinib in patients with alectinib-refractory ALK-positive NSCLC, J. Thorac. Oncol., 13, 1530, 10.1016/j.jtho.2018.06.005 Nishio, 2021, Brigatinib in Japanese patients with ALK-positive NSCLC previously treated with alectinib and other tyrosine kinase inhibitors: outcomes of the phase 2J-ALTA trial, J. Thorac. Oncol., 16, 452, 10.1016/j.jtho.2020.11.004 Kim, 2021, ALTA-2: phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib, Future Oncol., 17, 1709, 10.2217/fon-2020-1119 Cui, 2020, TPX-0131: a next generation macrocyclic ALK Inhibitor that overcomes ALK resistant mutations refractory to currently approved ALK inhibitors, 80 Murray, 2021, TPX-0131, a potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations, Mol. Cancer Ther., 10.1158/1535-7163.MCT-21-0221 Pelish, 2021, NVL-655 is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation, AACR Zhang, 2021, Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC., Lung Cancer, 10.1016/j.lungcan.2021.06.012 Ou, 2020, Catalog of 5’ fusion partners in ALK- positive NSCLC Circa 2020, JTO Clin. Res. Rep., 1 Heuckmann, 2012, Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants, Clin. Cancer Res., 18, 4682, 10.1158/1078-0432.CCR-11-3260 Workman, 2014, EML4-ALK fusions: propelling cancer but creating exploitable chaperone dependence, Cancer Discov., 4, 642, 10.1158/2159-8290.CD-14-0409 Dagogo-Jack, 2020, MET Alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer, Clin. Cancer Res., 26, 2535, 10.1158/1078-0432.CCR-19-3906 Lin, 2020, Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer, Ann. Oncol., 31, 1725, 10.1016/j.annonc.2020.09.015 Rosen, 2021, Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib, Clin. Cancer Res., 27, 34, 10.1158/1078-0432.CCR-20-2278 Zhu, 2021, Acquired tertiary MET resistances (MET D1228N and a novel LSM8-MET fusion) to selpercatinib and capmatinib combination in a KIF5B-RET+ NSCLC patient who acquired MET amplification as initial resistance to selpercatinib, J. Thorac. Oncol., 10.1016/j.jtho.2021.03.006 Coco, 2018, NTRK fusion-positive cancers and TRK inhibitor therapy, Nat. Rev. Clin. Oncol., 15, 731, 10.1038/s41571-018-0113-0 Bauer, 2019, Clinical management of adverse events associated with lorlatinib, Oncologist, 24, 1103, 10.1634/theoncologist.2018-0380 Nagasaka, 2020, A user's guide to lorlatinib, Crit. Rev. Oncol. Hematol., 151, 10.1016/j.critrevonc.2020.102969 Socinski, 2018, Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC, N. Engl. J. Med., 378, 2288, 10.1056/NEJMoa1716948 https://www.ema.europa.eu/en/documents/overview/tecentriq-epar-medicine-overview_en.pdf (assessed June 11, 2021) 2021. Reck, 2019, IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations. Presented at: 2019 European Society of Medical Oncology, Ann. Oncol., 30, ii38 Reck, 2019, Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial, Lancet Respir. Med., 7, 387, 10.1016/S2213-2600(19)30084-0 Lin, 2020, Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive NSCLC refractory to second-generation ALK inhibitors, J. Thorac. Oncol., 15, 258, 10.1016/j.jtho.2019.10.014 Ou, 2014, Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-alpha-, NTRK1-) non-small cell lung cancer globally?, Front. Oncol., 4, 58, 10.3389/fonc.2014.00058 Lin, 2018, Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer, J. Clin. Oncol., 36, 1199, 10.1200/JCO.2017.76.2294